Preoperative chemotherapy: Updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27

Priya Rastogi, Stewart J. Anderson, Harry D. Bear, Charles E. Geyer, Morton S. Kahlenberg, André Robidoux, Richard G. Margolese, James L. Hoehn, Victor G. Vogel, Shaker R. Dakhil, Deimante Tamkus, Karen M. King, Eduardo R. Pajon, Mary Johanna Wright, Jean Robert, Soonmyung Paik, Eleftherios P. Mamounas, Norman Wolmark

Research output: Contribution to journalArticle

1013 Citations (Scopus)

Abstract

Purpose: National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-18 was designed to determine whether four cycles of doxorubicin and cyclophosphamide (AC) administered preoperatively improved breast cancer disease-free survival (DFS) and overall survival (OS) compared with AC administered postoperatively. Protocol B-27 was designed to determine the effect of adding docetaxel (T) to preoperative AC on tumor response rates, DFS, and OS. Patients and Methods: Analyses were limited to eligible patients. In B-18, 751 patients were assigned to receive preoperative AC, and 742 patients were assigned to receive postoperative AC. In B-27, 784 patients were assigned to receive preoperative AC followed by surgery, 783 patients were assigned to AC followed by T and surgery, and 777 patients were assigned to AC followed by surgery and then T. Results: Results from B-18 show no statistically significant differences in DFS and OS between the two groups. However, there were trends in favor of preoperative chemotherapy for DFS and OS in women less than 50 years old (hazard ratio [HR] = 0.85, P = .09 for DFS; HR = 0.81, P = .06 for OS). DFS conditional on being event free for 5 years also demonstrated a strong trend in favor of the preoperative group (HR = 0.81, P = .053). Protocol B-27 results demonstrated that the addition of T to AC did not significantly impact DFS or OS. Preoperative T added to AC significantly increased the proportion of patients having pathologic complete responses (pCRs) compared with preoperative AC alone (26% v 13%, respectively; P < .0001). In both studies, patients who achieved a pCR continue to have significantly superior DFS and OS outcomes compared with patients who did not. Conclusion: B-18 and B-27 demonstrate that preoperative therapy is equivalent to adjuvant therapy. B-27 also showed that the addition of preoperative taxanes to AC improves response.

Original languageEnglish (US)
Pages (from-to)778-785
Number of pages8
JournalJournal of Clinical Oncology
Volume26
Issue number5
DOIs
StatePublished - Feb 2 2008

Fingerprint

Cyclophosphamide
Breast
Drug Therapy
Disease-Free Survival
Survival
docetaxel
Taxoids
Breast Diseases
Doxorubicin
Breast Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., ... Wolmark, N. (2008). Preoperative chemotherapy: Updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. Journal of Clinical Oncology, 26(5), 778-785. https://doi.org/10.1200/JCO.2007.15.0235

Preoperative chemotherapy : Updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. / Rastogi, Priya; Anderson, Stewart J.; Bear, Harry D.; Geyer, Charles E.; Kahlenberg, Morton S.; Robidoux, André; Margolese, Richard G.; Hoehn, James L.; Vogel, Victor G.; Dakhil, Shaker R.; Tamkus, Deimante; King, Karen M.; Pajon, Eduardo R.; Wright, Mary Johanna; Robert, Jean; Paik, Soonmyung; Mamounas, Eleftherios P.; Wolmark, Norman.

In: Journal of Clinical Oncology, Vol. 26, No. 5, 02.02.2008, p. 778-785.

Research output: Contribution to journalArticle

Rastogi, P, Anderson, SJ, Bear, HD, Geyer, CE, Kahlenberg, MS, Robidoux, A, Margolese, RG, Hoehn, JL, Vogel, VG, Dakhil, SR, Tamkus, D, King, KM, Pajon, ER, Wright, MJ, Robert, J, Paik, S, Mamounas, EP & Wolmark, N 2008, 'Preoperative chemotherapy: Updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27', Journal of Clinical Oncology, vol. 26, no. 5, pp. 778-785. https://doi.org/10.1200/JCO.2007.15.0235
Rastogi, Priya ; Anderson, Stewart J. ; Bear, Harry D. ; Geyer, Charles E. ; Kahlenberg, Morton S. ; Robidoux, André ; Margolese, Richard G. ; Hoehn, James L. ; Vogel, Victor G. ; Dakhil, Shaker R. ; Tamkus, Deimante ; King, Karen M. ; Pajon, Eduardo R. ; Wright, Mary Johanna ; Robert, Jean ; Paik, Soonmyung ; Mamounas, Eleftherios P. ; Wolmark, Norman. / Preoperative chemotherapy : Updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. In: Journal of Clinical Oncology. 2008 ; Vol. 26, No. 5. pp. 778-785.
@article{37e87a8c07cc4ef4b64e9e2e9f1c2bf3,
title = "Preoperative chemotherapy: Updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27",
abstract = "Purpose: National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-18 was designed to determine whether four cycles of doxorubicin and cyclophosphamide (AC) administered preoperatively improved breast cancer disease-free survival (DFS) and overall survival (OS) compared with AC administered postoperatively. Protocol B-27 was designed to determine the effect of adding docetaxel (T) to preoperative AC on tumor response rates, DFS, and OS. Patients and Methods: Analyses were limited to eligible patients. In B-18, 751 patients were assigned to receive preoperative AC, and 742 patients were assigned to receive postoperative AC. In B-27, 784 patients were assigned to receive preoperative AC followed by surgery, 783 patients were assigned to AC followed by T and surgery, and 777 patients were assigned to AC followed by surgery and then T. Results: Results from B-18 show no statistically significant differences in DFS and OS between the two groups. However, there were trends in favor of preoperative chemotherapy for DFS and OS in women less than 50 years old (hazard ratio [HR] = 0.85, P = .09 for DFS; HR = 0.81, P = .06 for OS). DFS conditional on being event free for 5 years also demonstrated a strong trend in favor of the preoperative group (HR = 0.81, P = .053). Protocol B-27 results demonstrated that the addition of T to AC did not significantly impact DFS or OS. Preoperative T added to AC significantly increased the proportion of patients having pathologic complete responses (pCRs) compared with preoperative AC alone (26{\%} v 13{\%}, respectively; P < .0001). In both studies, patients who achieved a pCR continue to have significantly superior DFS and OS outcomes compared with patients who did not. Conclusion: B-18 and B-27 demonstrate that preoperative therapy is equivalent to adjuvant therapy. B-27 also showed that the addition of preoperative taxanes to AC improves response.",
author = "Priya Rastogi and Anderson, {Stewart J.} and Bear, {Harry D.} and Geyer, {Charles E.} and Kahlenberg, {Morton S.} and Andr{\'e} Robidoux and Margolese, {Richard G.} and Hoehn, {James L.} and Vogel, {Victor G.} and Dakhil, {Shaker R.} and Deimante Tamkus and King, {Karen M.} and Pajon, {Eduardo R.} and Wright, {Mary Johanna} and Jean Robert and Soonmyung Paik and Mamounas, {Eleftherios P.} and Norman Wolmark",
year = "2008",
month = "2",
day = "2",
doi = "10.1200/JCO.2007.15.0235",
language = "English (US)",
volume = "26",
pages = "778--785",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Preoperative chemotherapy

T2 - Updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27

AU - Rastogi, Priya

AU - Anderson, Stewart J.

AU - Bear, Harry D.

AU - Geyer, Charles E.

AU - Kahlenberg, Morton S.

AU - Robidoux, André

AU - Margolese, Richard G.

AU - Hoehn, James L.

AU - Vogel, Victor G.

AU - Dakhil, Shaker R.

AU - Tamkus, Deimante

AU - King, Karen M.

AU - Pajon, Eduardo R.

AU - Wright, Mary Johanna

AU - Robert, Jean

AU - Paik, Soonmyung

AU - Mamounas, Eleftherios P.

AU - Wolmark, Norman

PY - 2008/2/2

Y1 - 2008/2/2

N2 - Purpose: National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-18 was designed to determine whether four cycles of doxorubicin and cyclophosphamide (AC) administered preoperatively improved breast cancer disease-free survival (DFS) and overall survival (OS) compared with AC administered postoperatively. Protocol B-27 was designed to determine the effect of adding docetaxel (T) to preoperative AC on tumor response rates, DFS, and OS. Patients and Methods: Analyses were limited to eligible patients. In B-18, 751 patients were assigned to receive preoperative AC, and 742 patients were assigned to receive postoperative AC. In B-27, 784 patients were assigned to receive preoperative AC followed by surgery, 783 patients were assigned to AC followed by T and surgery, and 777 patients were assigned to AC followed by surgery and then T. Results: Results from B-18 show no statistically significant differences in DFS and OS between the two groups. However, there were trends in favor of preoperative chemotherapy for DFS and OS in women less than 50 years old (hazard ratio [HR] = 0.85, P = .09 for DFS; HR = 0.81, P = .06 for OS). DFS conditional on being event free for 5 years also demonstrated a strong trend in favor of the preoperative group (HR = 0.81, P = .053). Protocol B-27 results demonstrated that the addition of T to AC did not significantly impact DFS or OS. Preoperative T added to AC significantly increased the proportion of patients having pathologic complete responses (pCRs) compared with preoperative AC alone (26% v 13%, respectively; P < .0001). In both studies, patients who achieved a pCR continue to have significantly superior DFS and OS outcomes compared with patients who did not. Conclusion: B-18 and B-27 demonstrate that preoperative therapy is equivalent to adjuvant therapy. B-27 also showed that the addition of preoperative taxanes to AC improves response.

AB - Purpose: National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-18 was designed to determine whether four cycles of doxorubicin and cyclophosphamide (AC) administered preoperatively improved breast cancer disease-free survival (DFS) and overall survival (OS) compared with AC administered postoperatively. Protocol B-27 was designed to determine the effect of adding docetaxel (T) to preoperative AC on tumor response rates, DFS, and OS. Patients and Methods: Analyses were limited to eligible patients. In B-18, 751 patients were assigned to receive preoperative AC, and 742 patients were assigned to receive postoperative AC. In B-27, 784 patients were assigned to receive preoperative AC followed by surgery, 783 patients were assigned to AC followed by T and surgery, and 777 patients were assigned to AC followed by surgery and then T. Results: Results from B-18 show no statistically significant differences in DFS and OS between the two groups. However, there were trends in favor of preoperative chemotherapy for DFS and OS in women less than 50 years old (hazard ratio [HR] = 0.85, P = .09 for DFS; HR = 0.81, P = .06 for OS). DFS conditional on being event free for 5 years also demonstrated a strong trend in favor of the preoperative group (HR = 0.81, P = .053). Protocol B-27 results demonstrated that the addition of T to AC did not significantly impact DFS or OS. Preoperative T added to AC significantly increased the proportion of patients having pathologic complete responses (pCRs) compared with preoperative AC alone (26% v 13%, respectively; P < .0001). In both studies, patients who achieved a pCR continue to have significantly superior DFS and OS outcomes compared with patients who did not. Conclusion: B-18 and B-27 demonstrate that preoperative therapy is equivalent to adjuvant therapy. B-27 also showed that the addition of preoperative taxanes to AC improves response.

UR - http://www.scopus.com/inward/record.url?scp=39149111633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39149111633&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.15.0235

DO - 10.1200/JCO.2007.15.0235

M3 - Article

C2 - 18258986

AN - SCOPUS:39149111633

VL - 26

SP - 778

EP - 785

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -